Minervax
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Tech Stack (18 technologies)
Frequently Asked Questions
What technologies does Minervax use?+
Minervax uses 18 technologies including Contact Form 7, reCAPTCHA, WordPress.
What industry is Minervax in?+
Minervax operates in the Biotechnology industry.
Where is Minervax based?+
Minervax is headquartered in Germany.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026